![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChemCID | |
ChemSpider |
|
UNII | |
CompTox Dashboard(EPA) | |
ECHA InfoCard | 100.207.294![]() |
Chemical and physical data | |
Formula | C20H21NO |
Molar mass | 291.394 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
PRC200-SS is an experimental drug of thetriple reuptake inhibitor class that was investigated by theMayo Clinic.[1][2]
Preclinical toxicology studies of PRC200-SS incynomolgus monkeys showed dose proportional kidney toxicity,[3] precluding any furtherdrug development.